Supplementation with live microbial strains is a novel approach to modulate the synergy between the microbiome and the gastrointestinal system to treat hyperuricemia.
A large proportion of the population in the Western world suffers from elevated serum uric acid levels, hyperuricemia. The condition is a causal risk factor for serious diseases such as gout, hypertension, chronic kidney disease and type 2 diabetes.
Current standard treatment for hyperuricemia only brings 50% of patients below the recommended treatment target leaving a significant unmet medical need for safe and efficacious treatments.
The product will be developed by an innovative combination of a food-supplement development path with pharmaceutical drug development approaches. This accelerates development timelines significantly.
The product may be developed for multiple applications as food-supplement, medical food or drug.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Zürich, Zürich 8038, Ch
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.beotherapeutics.com
- Keywords
- LyteGro.
- HQ
- Zürich, Zürich
Beo Therapeutics Questions
Beo Therapeutics's website is http://www.beotherapeutics.com
Beo Therapeutics's LinkedIn profile is https://ch.linkedin.com/company/beotherapeutics
Beo Therapeutics has
3 employees.
View email and phone details for 3
employees at Beo Therapeutics.
Beo Therapeutics's industry is
Pharmaceutical Manufacturing
Beo Therapeutics's top competitors are
Bac3gel,
Seqbiome,
Bioinnovation Institute,
Cc Bio,
Micreos,
Lytegro,
Alba Health,
Treat Therapeutics,
Neobiosys,
Biocortex.
Beo Therapeutics's categories are Pharmaceutical Manufacturing
Beo Therapeutics's founding year is 2019
